[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 49 of about 49
1. Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, Abruzzo LV, Kantarjian HM, Medeiros LJ, Wang SA: Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood; 2010 Mar 11;115(10):1985-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification.
  • Acute erythroid leukemia (AEL) is a rare type of acute myeloid leukemia (AML) for which diagnostic criteria have been refined in the 2008 World Health Organization (WHO) classification of AML.
  • We conducted a retrospective, multi-institutional study of patients with AEL and compared them with patients with MDS or AML-MRC with erythroid hyperplasia (> or = 50% erythroid cells).
  • The median overall survival (OS) of all AEL patients was 8 months, comparable with that of patients with MDS or AML-MRC with erythroid hyperplasia.
  • Our findings suggest that AEL is in the continuum of MDS and AML with erythroid hyperplasia, where karyotype rather than an arbitrary blast cutoff represents the most important prognostic factor.
  • [MeSH-major] Classification / methods. Leukemia, Erythroblastic, Acute / classification. World Health Organization
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Chromosome Aberrations. Female. Humans. Male. Middle Aged. Polymorphism, Genetic. Retrospective Studies. Survival Analysis. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2002 Aug;16(8):1399-401 [12145675.001]
  • [Cites] Leukemia. 2009 Dec;23(12):2275-80 [19741728.001]
  • [Cites] Leuk Res. 2003 May;27(5):397-404 [12620291.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2895-6 [12642345.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Blood. 1992 Dec 1;80(11):2873-82 [1450412.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Leuk Res. 1997 May;21(5):415-25 [9225069.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1567-72 [16049515.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Dec;163(2):113-22 [16337853.001]
  • [Cites] Br J Haematol. 2006 Jan;132(2):162-7 [16398650.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):530-3 [16938665.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):197-205 [17210514.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4385-95 [17726160.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1855-61 [18056840.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4791-7 [18695255.001]
  • [Cites] Mod Pathol. 2008 Nov;21(11):1394-402 [18839018.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1906-8 [19131546.001]
  • [Cites] Mod Pathol. 2009 Aug;22(8):1023-31 [19430420.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3135-40 [12384410.001]
  • (PMID = 20040759.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024153
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2942006
  •  go-up   go-down


2. Kasyan A, Medeiros LJ, Zuo Z, Santos FP, Ravandi-Kashani F, Miranda R, Vadhan-Raj S, Koeppen H, Bueso-Ramos CE: Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol; 2010 Aug;23(8):1113-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease.
  • The diagnostic criteria for acute erythroid leukemia have been controversial since this disease was initially described.
  • Using the current World Health Organization classification criteria, we retrospectively reviewed cases of acute myeloid leukemia or myelodysplastic syndrome in which erythroid precursors were >or=50% of the bone marrow nucleated cell population and the diagnosis of erythroleukemia was considered using older classification schemes.
  • We collected 90 cases and separated them into four diagnostic groups: acute erythroid leukemia, erythroleukemia or erythroid/myeloid type (n=20); acute myeloid leukemia with myelodysplasia-related changes (n=22); therapy-related acute myeloid leukemia (n=32); and refractory anemia with excess blasts and preceding or concurrent history of erythropoietin therapy for anemia (n=16).
  • Patients with acute erythroid leukemia were the youngest patient group and had the best overall survival.
  • There was a statistically significant difference in overall survival between patients with acute erythroid leukemia versus acute myeloid leukemia with myelodysplasia-related changes (P=0.003) and between patients with acute erythroid leukemia versus therapy-related acute myeloid leukemia (P<0.0001).
  • The presence of complex cytogenetic abnormalities (>3) was the only statistically significant independent variable that adversely affected survival in the acute erythroid leukemia group.
  • Our data suggest that acute erythroid leukemia, as currently defined in the World Health Organization classification, has become a rare disease.
  • In addition, our data suggest that the current definition of acute erythroid leukemia, erythroleukemia type remains heterogeneous.
  • One subset of acute erythroid leukemia patients has relatively low blast counts and are diploid.
  • [MeSH-major] Erythroid Cells / pathology. Leukemia, Erythroblastic, Acute / pathology. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anemia, Refractory / pathology. Bone Marrow Cells / pathology. Bone Marrow Transplantation. Child. Chromosome Aberrations. Erythroblasts / pathology. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Texas / epidemiology. World Health Organization. Young Adult

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473273.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K, Jamieson CH: Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell; 2008 Apr;13(4):321-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
  • Polycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized by mutant JAK2 (JAK2V617F) signaling, erythrocyte overproduction, and a propensity for thrombosis, progression to myelofibrosis, or acute leukemia.
  • In this study, JAK2V617F expression by human hematopoietic progenitors promoted erythroid colony formation and erythroid engraftment in a bioluminescent xenogeneic immunocompromised mouse transplantation model.
  • TG101348 treatment decreased GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F+ progenitor differentiation, and inhibited STAT5 as well as GATA S310 phosphorylation.
  • [MeSH-major] Cell Differentiation / drug effects. Erythroid Precursor Cells / enzymology. Erythroid Precursor Cells / pathology. Janus Kinase 2 / antagonists & inhibitors. Polycythemia Vera / enzymology. Polycythemia Vera / pathology. Protein Kinase Inhibitors / pharmacology
  • [MeSH-minor] Adult. Aged. Amino Acid Substitution. Animals. Base Sequence. Female. Humans. Male. Mice. Middle Aged. Molecular Sequence Data. Phenylalanine / genetics. Signal Transduction / drug effects. Stem Cell Transplantation. Valine / genetics


Advertisement
4. Lin IJ, Zhou Z, Crusselle-Davis VJ, Moghimi B, Gandhi K, Anantharaman A, Pantic D, Huang S, Jayandharan G, Zhong L, Srivastava A, Bungert J: Calpeptin increases the activity of upstream stimulatory factor and induces high level globin gene expression in erythroid cells. J Biol Chem; 2009 Jul 24;284(30):20130-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calpeptin increases the activity of upstream stimulatory factor and induces high level globin gene expression in erythroid cells.
  • Differentiation of erythroid cells is regulated by cell signaling pathways including those that change the intracellular concentration of calcium.
  • Treatment of MEL cells with the specific calpain inhibitor calpeptin increased the levels of USF and strongly induced expression of the adult alpha- and beta-globin genes.
  • Calpeptin also induced high level alpha- and beta-globin gene expression in primary CD71-positive erythroid progenitor cells.
  • The combined data suggest that inhibition of calpain activity is required for erythroid differentiation-associated increase in globin gene expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):369-78 [8995271.001]
  • [Cites] Nucleic Acids Res. 1993 Nov 11;21(22):5092-100 [8255762.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50350-7 [15385559.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):146-55 [15752978.001]
  • [Cites] Pigment Cell Res. 2005 Oct;18(5):337-48 [16162174.001]
  • [Cites] Cell Biochem Biophys. 2006;45(2):147-56 [16757815.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(18):6832-43 [16943425.001]
  • [Cites] Science. 2006 Oct 6;314(5796):122-5 [17023658.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):1037-46 [17272500.001]
  • [Cites] FEBS J. 2007 Dec;274(23):6065-73 [17970752.001]
  • [Cites] Mol Cell. 2007 Dec 14;28(5):810-22 [18082606.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1920-3 [18063756.001]
  • [Cites] Curr Opin Immunol. 2008 Jun;20(3):250-8 [18515054.001]
  • [Cites] Exp Hematol. 2008 Sep;36(9):1057-72 [18718415.001]
  • [Cites] Biol Reprod. 2009 Jan;80(1):24-33 [18768914.001]
  • [Cites] Nature. 2009 Feb 26;457(7233):1103-8 [19242469.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(4):1140-8 [10648599.001]
  • [Cites] J Exp Med. 2000 Nov 20;192(10):1479-90 [11085749.001]
  • [Cites] Biol Chem. 2002 May;383(5):757-64 [12108540.001]
  • [Cites] Cell. 2002 Nov 15;111(4):529-41 [12437926.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):1292-301 [12582249.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):731-801 [12843408.001]
  • [Cites] Cell. 1976 Oct;9(2):221-9 [975244.001]
  • [Cites] J Cell Biol. 1981 Aug;90(2):542-4 [6793600.001]
  • [Cites] J Biol Chem. 1985 Apr 25;260(8):4884-9 [3857230.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Blood. 1991 Mar 15;77(6):1362-70 [2001459.001]
  • [Cites] Nature. 1993 Jan 28;361(6410):315-25 [8381210.001]
  • [Cites] Biochim Biophys Acta. 1993 Aug 18;1178(2):207-14 [8347679.001]
  • [Cites] J Biol Chem. 1993 Sep 5;268(25):18824-34 [8360172.001]
  • [Cites] Nature. 1993 Sep 23;365(6444):355-9 [8377828.001]
  • [Cites] Exp Cell Res. 2005 Jan 1;302(1):1-10 [15541720.001]
  • (PMID = 19491096.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK052356-10; United States / NIDDK NIH HHS / DK / R01 DK052356; United States / NIDDK NIH HHS / DK / DK052356-15A1; United States / NHLBI NIH HHS / HL / R01 HL090589; United States / NIDDK NIH HHS / DK / DK052356; United States / NIDDK NIH HHS / DK / R01 DK052356-10; United States / NIDDK NIH HHS / DK / R01 DK052356-15A1; United States / NHLBI NIH HHS / HL / HL090589
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dipeptides; 0 / Enzyme Inhibitors; 0 / Upstream Stimulatory Factors; 117591-20-5 / calpeptin; 9004-22-2 / Globins; EC 2.7.7.- / RNA Polymerase II; EC 3.4.22.- / Calpain; EC 3.4.22.- / m-calpain
  • [Other-IDs] NLM/ PMC2740439
  •  go-up   go-down


5. Liu J, Lu DP, Zhang Y: [The prognosis and cytogenetic characteristics of acute erythroid leukemia: a report of 55 cases]. Zhonghua Nei Ke Za Zhi; 2006 Sep;45(9):738-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The prognosis and cytogenetic characteristics of acute erythroid leukemia: a report of 55 cases].
  • OBJECTIVE: To explore the prognosis and cytogenetic characteristics of acute erythroid leukemia.
  • METHODS: We selected 55 patients with acute erythroid leukemia and reviewed the cytogenetic characteristics of these cases.
  • With case-control studies, 55 patients were classified as primary or MDS transformed leukemia depending on the absence or presence of MDS history.
  • Among them, the complete remission rate of acute erythroid leukemia with MDS history was lower than that without MDS history (42.8% vs 85.2%, P < 0.05).
  • The complete remission rate of acute erythroid leukemia with aberrant karyotypes was lower than that with normal karyotypes (37.0% vs 83.3%, P < 0.01).
  • CONCLUSIONS: Acute erythroid leukemia patients with aberrant karyotypes or MDS history are usually resistant to chemotherapy.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / diagnosis. Leukemia, Erythroblastic, Acute / genetics
  • [MeSH-minor] Adult. Chromosome Aberrations. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Karyotyping. Male. Prognosis. Retrospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166448.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Shyu YC, Wen SC, Lee TL, Chen X, Hsu CT, Chen H, Chen RL, Hwang JL, Shen CK: Chromatin-binding in vivo of the erythroid kruppel-like factor, EKLF, in the murine globin loci. Cell Res; 2006 Apr;16(4):347-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromatin-binding in vivo of the erythroid kruppel-like factor, EKLF, in the murine globin loci.
  • EKLF is an erythroid-specific, zinc finger-containing transcription factor essential for the activation of the mammalian beta globin gene in erythroid cells of definitive lineage.
  • We have prepared a polyclonal anti-mouse EKLF antibody suitable for Western blotting and immunoprecipitation (IP) qualities, and used it to define the expression patterns of the EKLF protein during mouse erythroid development.
  • The DMSO-induced bindings of EKLF as well as three other proteins, namely, RNA polymerase II, acetylated histone H3, and methylated histone H3, were not abolished but significantly lowered in CB3, a MEL-derived cell line with null-expression of p45/NF-E2, an erythroid-enriched factor needed for activation of the mammalian globin loci.
  • Interestingly, binding of EKLF in vivo was also detected in the mouse alpha-like globin locus, at the adult alpha globin promoter and its far upstream regulatory element alpha-MRE (HS26).
  • [MeSH-minor] Animals. Cells, Cultured. Chromatin Immunoprecipitation. Erythroid Cells / immunology. Gene Expression. Gene Expression Regulation. Humans. Leukemia, Erythroblastic, Acute. Mice. Multigene Family. NF-E2 Transcription Factor, p45 Subunit / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617330.001).
  • [ISSN] 1001-0602
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Kruppel-Like Transcription Factors; 0 / NF-E2 Transcription Factor, p45 Subunit; 0 / Nfe2 protein, mouse; 0 / erythroid Kruppel-like factor; 9004-22-2 / Globins
  •  go-up   go-down


7. Tang X, Long C, Wang C, Xiao G: [Expression of DLK1 gene in acute leukemias and its function in erythroid differentiation of K562 cell line]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Sep;34(9):886-91
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of DLK1 gene in acute leukemias and its function in erythroid differentiation of K562 cell line].
  • OBJECTIVE: To determine the expression of DLK1 gene in acute leukemias (AL) and its function in erythroid differentiation of K562 cells.
  • METHODS: We detected the expression of DLK1 gene in 65 different acute leukemia categories (a test group) and 34 normal bone marrow controls (a control group) with RT-PCR.
  • The K562 cell line was induced to erythroid differentiation by hemin.
  • We observed the relationship between its expression and erythroid differentiation.
  • RESULTS: Both leukemia cells and normal marrow cells expressed DLK1.
  • The expression of DLK1 mRNA in patients in the test group was higher than that in the control group (P=0.018), while there was no significance between acute lymphoblastic leukemia and acute myelogenous leukemia (P>0.05).The expression of DLK1 mRNA in the test group at onset had no relation with the WBC and platelet count in the total peripheral blood, and the same was true for blast cell rates in bone marrow cells.The level of DLK1 protein in the test group was higher than that in the control group, which was consistent with the mRNA expression (P=0.042).
  • The expression of DLK1 mRNA decreased gradually with K562 cells towards hemin-induced erythroid differentiation.
  • CONCLUSION: DLK1 gene may be involved in leukemia,but the mRNA level of DLK1 has no relation with some clinical characteristics of AL patients at onset.
  • DLK1 may inhibit the erythroid differentiation of K562 cells.
  • [MeSH-major] Cell Differentiation / genetics. Cell Transformation, Neoplastic / genetics. Erythroid Cells / pathology. Intercellular Signaling Peptides and Proteins / metabolism. Leukemia / genetics. Membrane Proteins / metabolism
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Case-Control Studies. Child. Child, Preschool. Erythroid Precursor Cells / pathology. Female. Humans. K562 Cells. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779261.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DLK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


8. Heo HS, Kim JH, Lee YJ, Kim SH, Cho YS, Kim CG: Microarray profiling of genes differentially expressed during erythroid differentiation of murine erythroleukemia cells. Mol Cells; 2005 Aug 31;20(1):57-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray profiling of genes differentially expressed during erythroid differentiation of murine erythroleukemia cells.
  • Murine erythroleukemia (MEL) cells are widely used to study erythroid differentiation thanks to their ability to terminally differentiate in vitro in response to chemical induction.
  • At the molecular level, not much is known of their terminal differentiation apart from activation of adult-type globin gene expression.
  • These genetic markers should be a valuable resource both as potential regulators in functional studies of erythroid differentiation, and as straightforward cell type markers.
  • [MeSH-major] Cell Differentiation / genetics. Gene Expression Profiling. Leukemia, Erythroblastic, Acute / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258242.001).
  • [ISSN] 1016-8478
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Acetamides; 0 / Genetic Markers; LA133J59VU / hexamethylene bisacetamide
  •  go-up   go-down


9. Jun KR, Park CJ, Cho YW, Jang S, Chi HS, Lee JH, Lee KH: Recommendation of the use of myeloblast percentage among non-erythroid cells instead of percentage among total nucleated cells for therapeutic response assessment in acute erythroid leukemia. Leuk Lymphoma; 2006 Apr;47(4):683-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recommendation of the use of myeloblast percentage among non-erythroid cells instead of percentage among total nucleated cells for therapeutic response assessment in acute erythroid leukemia.
  • The diagnostic criteria of acute erythroid leukemias (AEL) has been revised by WHO in 2001.
  • The National Cancer Institute (NCI) published a set of standardized diagnostic and response criteria for acute myeloid leukemia in 1990, which was revised in 2003.
  • (ii) myeloblast percentage among non-erythroid cells (NEC) and cellularity;.
  • (iii) erythroid series percentage among TNC;.
  • (iv) pronormoblast percentage among erythroid cells;.
  • (vi) maturation arrest index; and (vii) disappearance of erythroid dysplasia.
  • [MeSH-major] Granulocyte Precursor Cells / cytology. Leukemia, Erythroblastic, Acute / classification. Leukemia, Erythroblastic, Acute / therapy. Medical Oncology / standards
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690527.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Srinivas U, Kumar R, Pati H, Saxena R, Tyagi S: Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify? Hematology; 2007 Oct;12(5):381-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify?
  • The clinico-hematological profile of 40 cases of acute erythroleukemia (AEL) was evaluated.
  • As AEL is biologically an "erythroid predominant" disease, two ratios (PE/MB, PE/TEC) with proerythroblasts as numerator have been formulated.
  • There were 29 M6a, 2M6b,and 9 M6 c patients, which were subclassified using the criteria proposed by Mazzella et al.
  • The subclassification of AEL becomes essential especially in the era of lineage-targeted therapies, which can lead to the development and use of erythroid specific treatments in the near future.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / classification
  • [MeSH-minor] Adult. Age Factors. Aged. Cell Count. Erythroblasts. Erythroid Cells. Female. Granulocyte Precursor Cells. Humans. Incidence. Male. Middle Aged. Sex Factors

  • Genetic Alliance. consumer health - Acute Erythroleukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852448.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Martínez-Jaramillo G, Vela-Ojeda J, Sánchez-Valle E, Montesinos JJ, Mayani H: In vitro functional alterations in the hematopoietic system of adult patients with acute lymphoblastic leukemia. Leuk Res; 2007 Jan;31(1):83-9
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro functional alterations in the hematopoietic system of adult patients with acute lymphoblastic leukemia.
  • In previous studies, we have demonstrated that progenitor cell-enriched marrow cell populations from patients with myeloid leukemia - including both acute (AML) and chronic (CML) - show severe functional alterations when cultured in stroma-free liquid cultures supplemented with stimulatory cytokines.
  • In trying to expand our characterization of the biology of leukemic cells, in the present study we have used a similar approach and analyzed the in vitro growth of equivalent cell populations from patients with acute lymphoblastic leukemia (ALL).
  • The capacity to generate myeloid and erythroid progenitors was also significantly reduced in ALL cultures.
  • [MeSH-major] Bone Marrow Cells / pathology. Hematopoietic Stem Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Adult. Antigens, CD / blood. Antigens, CD34 / blood. Cell Division. Female. Hematopoiesis. Humans. Leukocyte Count. Male. Philadelphia Chromosome. Ploidies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16769114.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34
  •  go-up   go-down


12. Ryningen A, Stapnes C, Bruserud Ø: Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leuk Res; 2007 Sep;31(9):1303-13
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
  • Differentiation-inducing therapy with the DNA-methylation inhibitor Decitabine (5'-aza-deoxycytidine) and histone deacetylase (HDAC) inhibitors are now considered in acute myelogenous leukemia (AML).
  • Based on morphological criteria we identified four major colony types: (i) non-erythroid colonies, (ii) erythroid colonies that were detected only for a subset of patients and could be further sub classified into mature and immature forms, and (iii) intermediate colonies.
  • Erythroid differentiation was associated with low CD34 expression.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Differentiation. Epigenesis, Genetic / drug effects. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cell Cycle / drug effects. Cell Proliferation. DNA, Mitochondrial / metabolism. Enzyme Inhibitors / pharmacology. Female. Histone Deacetylase Inhibitors. Humans. Hydroxamic Acids / pharmacology. Male. Middle Aged. Myelodysplastic Syndromes / drug therapy. Phenylbutyrates / pharmacology. Thymidine / metabolism. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416413.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Mitochondrial; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Phenylbutyrates; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; 7WY7YBI87E / 4-phenylbutyric acid; M801H13NRU / Azacitidine; VC2W18DGKR / Thymidine
  •  go-up   go-down


13. Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B: Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol; 2010 Apr;89(4):365-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
  • At a median follow-up of 40 months, 58% of the patients achieved an erythroid response and 48% a cytogenetic response.
  • Thirty-six percent of patients progressed into acute myeloid leukaemia.
  • However, erythroid and cytogenetic responders had a significantly decreased risk of progression to acute myeloid leukaemia (p = 0.001 and p = 0.009, respectively) compared to non-responders.
  • Three and 5 years after study entry, the cumulative incidence of acute myeloid leukaemia for patients with a cytogenetic response was 10% and 21%, respectively, and for patients without cytogenetic response, it was 46% and 60%.
  • Patients with del(5q) myelodysplastic syndromes without erythroid or cytogenetic remission after treatment with lenalidomide have a high risk for clonal evolution and acute myeloid leukaemia progression.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 5. Erythroid Cells / drug effects. Leukemia, Myeloid, Acute / pathology. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / pathology. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Karyotyping. Male. Middle Aged. Remission Induction. Risk Factors. Treatment Failure

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19855965.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  •  go-up   go-down


14. Soupir CP, Vergilio JA, Dal Cin P, Muzikansky A, Kantarjian H, Jones D, Hasserjian RP: Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol; 2007 Apr;127(4):642-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
  • We performed a multi-institutional retrospective analysis of the morphologic features, immunophenotype, cytogenetics, and BCR-ABL transcript characterization of cases of Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML).
  • We compared these cases with cases of documented chronic myelogenous leukemia in myeloid blast crisis (CML-MBC).
  • Patients with Ph+ AML were less likely to have splenomegaly or peripheral basophilia and had lower bone marrow cellularity and myeloid/erythroid ratios than patients with CML-MBC.
  • Ph+ AML is a rare aggressive acute leukemia with some features distinct from CML-MBC.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Female. Fusion Proteins, bcr-abl / metabolism. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis


15. Mirabelli P, Di Noto R, Lo Pardo C, Morabito P, Abate G, Gorrese M, Raia M, Pascariello C, Scalia G, Gemei M, Mariotti E, Del Vecchio L: Extended flow cytometry characterization of normal bone marrow progenitor cells by simultaneous detection of aldehyde dehydrogenase and early hematopoietic antigens: implication for erythroid differentiation studies. BMC Physiol; 2008;8:13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended flow cytometry characterization of normal bone marrow progenitor cells by simultaneous detection of aldehyde dehydrogenase and early hematopoietic antigens: implication for erythroid differentiation studies.
  • BACKGROUND: Aldehyde dehydrogenase (ALDH) is a cytosolic enzyme highly expressed in hematopoietic precursors from cord blood and granulocyte-colony stimulating factor mobilized peripheral blood, as well as in bone marrow from patients with acute myeloblastic leukemia.
  • The goal of our work was to provide new information about the dissection of normal bone marrow progenitor cells based upon the simultaneous detection by flow cytometry of ALDH and early hematopoietic antigens, with particular attention to the expression of ALDH on erythroid precursors.
  • ii) fluorescence activated cell sorting of distinct subpopulations of progenitor cells, followed by in vitro induction of erythroid differentiation;.
  • Of interest, ALDH+CD34- population disclosed a straightforward erythroid commitment, on the basis of three orders of evidences.
  • [MeSH-minor] Adult. Antigens / analysis. Antigens / immunology. Cell Differentiation / immunology. Cells, Cultured. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2001 Jul;188(1):1-7 [11382917.001]
  • [Cites] Cytotherapy. 2007;9(6):569-76 [17882722.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):99-108 [12823351.001]
  • [Cites] Eur J Haematol. 2003 Nov;71(5):351-8 [14667198.001]
  • [Cites] Haematologica. 2004 May;89(5):594-8 [15136223.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2513-21 [1384786.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2664-71 [9531574.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9118-23 [10430905.001]
  • [Cites] Leukemia. 2005 May;19(5):776-83 [15789068.001]
  • [Cites] Blood. 2005 Jul 1;106(1):95-102 [15790790.001]
  • [Cites] Cytometry B Clin Cytom. 2006 Jan;70(1):39-44 [16353215.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2162-9 [16269619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12 [16857736.001]
  • [Cites] Exp Hematol. 2007 Feb;35(2):335-41 [17258082.001]
  • [Cites] Cytotherapy. 2007;9(3):259-74 [17464758.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1423-30 [17476279.001]
  • [Cites] Exp Hematol. 2007 Sep;35(9):1437-46 [17656008.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1165-72 [17666374.001]
  • [Cites] Stem Cells. 2003;21(1):15-20 [12529547.001]
  • (PMID = 18510759.001).
  • [ISSN] 1472-6793
  • [Journal-full-title] BMC physiology
  • [ISO-abbreviation] BMC Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens; EC 1.2.1.3 / Aldehyde Dehydrogenase
  • [Other-IDs] NLM/ PMC2426712
  •  go-up   go-down


16. Glaser S, Metcalf D, Wu L, Hart AH, DiRago L, Mifsud S, D'Amico A, Dagger S, Campo C, Chan AC, Izon DJ, Robb L: Enforced expression of the homeobox gene Mixl1 impairs hematopoietic differentiation and results in acute myeloid leukemia. Proc Natl Acad Sci U S A; 2006 Oct 31;103(44):16460-5
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enforced expression of the homeobox gene Mixl1 impairs hematopoietic differentiation and results in acute myeloid leukemia.
  • To assess the role of Mixl1 in the regulation of adult hematopoiesis, we overexpressed Mixl1 in murine bone marrow using a retroviral transduction/transplantation model.
  • Enforced expression of Mixl1 profoundly perturbed hematopoietic lineage commitment and differentiation, giving rise to abnormal myeloid progenitors and impairing erythroid and lymphoid differentiation.
  • Moreover, all mice reconstituted with Mixl1-transduced bone marrow developed fatal, transplantable acute myeloid leukemia with a mean latency period of 200 days.
  • [MeSH-major] Cell Differentiation. Hematopoiesis. Homeodomain Proteins / metabolism. Leukemia, Myeloid, Acute / metabolism. Leukemia, Myeloid, Acute / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2002 May;129(9):2181-93 [11959827.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3122-30 [16403910.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5006-18 [12077330.001]
  • [Cites] Development. 2002 Aug;129(15):3597-608 [12117810.001]
  • [Cites] Stem Cells. 2002;20(5):364-79 [12351808.001]
  • [Cites] Development. 2002 Nov;129(21):4901-14 [12397099.001]
  • [Cites] Dev Dyn. 2003 Mar;226(3):446-59 [12619131.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):149-58 [12696063.001]
  • [Cites] J Exp Med. 2003 Jul 21;198(2):293-303 [12874262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):817-22 [14718672.001]
  • [Cites] Cell. 1989 Jun 16;57(6):965-74 [2567635.001]
  • [Cites] Nature. 2000 Mar 9;404(6774):193-7 [10724173.001]
  • [Cites] Genes Dev. 2000 May 15;14(10):1279-89 [10817762.001]
  • [Cites] Dev Dyn. 2000 Dec;219(4):497-504 [11084649.001]
  • [Cites] Development. 2001 Jan;128(2):167-80 [11124113.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8398-402 [1978323.001]
  • [Cites] Curr Opin Cell Biol. 1995 Dec;7(6):862-9 [8608017.001]
  • [Cites] Nature. 1996 Jul 25;382(6589):357-60 [8684465.001]
  • [Cites] Mol Cell Biol. 1997 Jan;17(1):495-505 [8972230.001]
  • [Cites] Immunity. 1997 Jan;6(1):13-22 [9052833.001]
  • [Cites] Development. 1998 Jul;125(13):2371-80 [9609820.001]
  • [Cites] Development. 1998 Jul;125(14):2577-85 [9636073.001]
  • [Cites] EMBO J. 1998 Jul 1;17(13):3714-25 [9649441.001]
  • [Cites] Science. 1998 Jul 3;281(5373):91-6 [9651252.001]
  • [Cites] Development. 1998 Oct;125(20):3997-4006 [9735361.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3780-92 [9808572.001]
  • [Cites] Blood. 1999 Jan 15;93(2):488-99 [9885210.001]
  • [Cites] Development. 1999 Apr;126(8):1769-79 [10079237.001]
  • [Cites] Development. 1999 Oct;126(19):4193-200 [10477288.001]
  • [Cites] Mech Dev. 1999 Sep;87(1-2):189-92 [10495285.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1456-66 [15522959.001]
  • [Cites] Development. 2005 Mar;132(5):873-84 [15673572.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 12;333(4):1361-9 [15982639.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1328-30 [15931267.001]
  • [Cites] Blood. 2002 Jul 1;100(1):89-95 [12070013.001]
  • (PMID = 17060613.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Mixl1 protein, mouse
  • [Other-IDs] NLM/ PMC1637604
  •  go-up   go-down


17. Ayala RM, Martínez-López J, Albízua E, Diez A, Gilsanz F: Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. Am J Hematol; 2009 Feb;84(2):79-86
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia.
  • The aim of this study was to evaluate the biological correlation and prognostic impact of Gata-1, Gata-2, EKLF, and c-MPL transcript level in a group of 41 acute myeloid leukemia (AML) patients.
  • [MeSH-major] GATA1 Transcription Factor / physiology. GATA2 Transcription Factor / physiology. Gene Expression Regulation, Neoplastic. Kruppel-Like Transcription Factors / physiology. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / physiology. Receptors, Thrombopoietin / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow / pathology. Chromosome Aberrations. Disease-Free Survival. Erythropoiesis / genetics. Humans. Middle Aged. Neoplasms, Second Primary / genetics. Neoplasms, Second Primary / metabolism. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / pathology. Prognosis. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097174.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / GATA2 Transcription Factor; 0 / GATA2 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Neoplasm Proteins; 0 / Receptors, Thrombopoietin; 0 / erythroid Kruppel-like factor; 143641-95-6 / MPL protein, human
  •  go-up   go-down


18. Kransdorf EP, Wang SZ, Zhu SZ, Langston TB, Rupon JW, Ginder GD: MBD2 is a critical component of a methyl cytosine-binding protein complex isolated from primary erythroid cells. Blood; 2006 Oct 15;108(8):2836-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MBD2 is a critical component of a methyl cytosine-binding protein complex isolated from primary erythroid cells.
  • We have now chromatographically purified and characterized this complex from adult chicken primary erythroid cells.
  • In adult erythrocytes, significant enrichment for MBD2 is seen at the inactive rho-globin gene by chromatin immunoprecipitation assay, whereas no enrichment is observed at the active beta(A)-globin gene, demonstrating MBD2 binds to the methylated and transcriptionally silent rho-globin gene in vivo.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):536-46 [11756549.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6617-22 [16608912.001]
  • [Cites] Mol Cell. 2002 Jul;10(1):81-91 [12150909.001]
  • [Cites] J Biol Chem. 2002 Sep 20;277(38):35434-9 [12124384.001]
  • [Cites] Semin Cell Dev Biol. 2003 Feb;14(1):53-65 [12524008.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3441-6 [11719386.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):45988-95 [11590142.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):498-504 [12543808.001]
  • [Cites] J Cell Biochem. 2003 Apr 1;88(5):899-910 [12616529.001]
  • [Cites] Nucleic Acids Res. 2003 Mar 15;31(6):1765-74 [12626718.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7480-5 [12802011.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):723-34 [14527417.001]
  • [Cites] Science. 2003 Oct 31;302(5646):885-9 [14593183.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Nat Cell Biol. 2004 Jan;6(1):73-7 [14661024.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):980-5 [14715908.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 15;1677(1-3):52-7 [15020045.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):595-605 [15327775.001]
  • [Cites] J Lab Clin Med. 1972 Apr;79(4):526-40 [5021295.001]
  • [Cites] Dev Biol. 1974 Sep;40(1):174-85 [4415523.001]
  • [Cites] Ann N Y Acad Sci. 1974 Nov 29;241(0):170-82 [4530650.001]
  • [Cites] Nature. 1979 Aug 2;280(5721):419-20 [460418.001]
  • [Cites] Nucleic Acids Res. 1979 Dec 20;7(8):2369-85 [523320.001]
  • [Cites] Cell. 1980 Apr;19(4):947-58 [6247075.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Nov;77(11):6634-8 [6935674.001]
  • [Cites] Cell. 1981 May;24(2):393-401 [7237553.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jul;79(14):4428-31 [6181507.001]
  • [Cites] N Engl J Med. 1982 Dec 9;307(24):1469-75 [6183586.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Aug;80(15):4842-6 [6192443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jul;81(13):3954-8 [6204332.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(21):6618-22 [6208553.001]
  • [Cites] Mol Cell Biol. 1981 Mar;1(3):281-8 [6086008.001]
  • [Cites] Cell. 1999 Oct 29;99(3):247-57 [10555141.001]
  • [Cites] Genes Dev. 2000 Feb 1;14(3):313-27 [10673503.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9797-804 [10734134.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2379-84 [11001887.001]
  • [Cites] Genes Dev. 2001 Mar 15;15(6):710-23 [11274056.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):827-32 [11297506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4990-5 [11309512.001]
  • [Cites] Biochemistry. 1989 Mar 7;28(5):2281-7 [2470406.001]
  • [Cites] Cell. 1989 Aug 11;58(3):499-507 [2758464.001]
  • [Cites] Exp Cell Res. 1992 Feb;198(2):268-75 [1729133.001]
  • [Cites] Development. 1992 Aug;115(4):1149-64 [1451662.001]
  • [Cites] Exp Cell Res. 1993 Jun;206(2):335-43 [8500553.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2117-30 [8804307.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):575-80 [9012826.001]
  • [Cites] Biochimie. 1996;78(11-12):903-7 [9150866.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13724-9 [9391093.001]
  • [Cites] J Biol Chem. 1998 Jan 30;273(5):3082-9 [9446625.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):187-91 [9620779.001]
  • [Cites] Mol Cell. 1998 Jun;1(7):1021-31 [9651585.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6538-47 [9774669.001]
  • [Cites] Cell. 1998 Nov 25;95(5):625-36 [9845365.001]
  • [Cites] Immunity. 1998 Dec;9(6):765-75 [9881967.001]
  • [Cites] Immunity. 1999 Mar;10(3):345-55 [10204490.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):4035-48 [10406808.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1094-101 [15502823.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4632-42 [15542813.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2367-78 [15920470.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2354-66 [15920471.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(3):843-51 [16428440.001]
  • [Cites] J Biol Chem. 2002 Jan 18;277(3):1897-905 [11684679.001]
  • (PMID = 16778143.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK 29902
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MBD2 protein; 0 / Multiprotein Complexes; 9004-22-2 / Globins; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC1895583
  •  go-up   go-down


19. Sharma P, Singh T, Mishra D, Gaiha M: Parvovirus B-19 induced acute pure red cell aplasia in patients with chronic lymphocytic leukemia and neurofibromatosis type-1. Hematology; 2006 Aug;11(4):257-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parvovirus B-19 induced acute pure red cell aplasia in patients with chronic lymphocytic leukemia and neurofibromatosis type-1.
  • We present two cases, an adult patient with chronic lymphocytic leukemia (CLL) and a child with neurofibromatosis type-1 (NF-1), where the abrupt appearance of severe anemia raised ominous clinical suspicions.
  • Evidence of recent parvovirus B19 infection in association with the selective erythroid precursor deficiency in marrow helped exclude other etiologies.
  • An association of NF-1 with acute PRCA has not been described in indexed English literature in the past.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Neurofibromatosis 1 / complications. Parvoviridae Infections / complications. Parvovirus B19, Human / pathogenicity. Red-Cell Aplasia, Pure / etiology
  • [MeSH-minor] Acute Disease. Bone Marrow / pathology. Bone Marrow / virology. Child. Diagnosis, Differential. Erythroid Precursor Cells / pathology. Hematologic Diseases / diagnosis. Humans. Infection / diagnosis. Male. Middle Aged


20. Schetelig J, Breitschaft A, Kröger N, Zabelina T, Ebell W, Bornhäuser M, Haack A, Ehninger G, Salama A, Siegert W, Cooperative Transplantations Study Group: After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B. Transfusion; 2005 May;45(5):779-87
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
  • BACKGROUND: Isohemagglutinins directed against the donor blood group frequently delay erythroid engraftment after major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation (HPCT).
  • CONCLUSION: These results indicate that the immunogenicity of the ABO antigen plays an important role for the kinetics of erythroid engraftment after ABO-mismatched HPCT.
  • [MeSH-major] ABO Blood-Group System / immunology. Blood Grouping and Crossmatching. Graft vs Host Disease / mortality. Hematopoietic Stem Cell Transplantation / mortality. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Blood Transfusion / statistics & numerical data. Child. Child, Preschool. Female. Graft Survival / immunology. Humans. Infant. Male. Middle Aged. Neutrophils / transplantation. Retrospective Studies. Risk Factors. Survival Analysis. Transplantation Conditioning

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847669.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System
  •  go-up   go-down


21. Dorantes-Acosta E, Chávez-González A, Santos JI, Medina-Sanson A, Mayani H: Defective in vitro growth of primitive hematopoietic cells from pediatric patients with acute myeloid leukemia. Pediatr Blood Cancer; 2008 Dec;51(6):741-6
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective in vitro growth of primitive hematopoietic cells from pediatric patients with acute myeloid leukemia.
  • BACKGROUND: Acute myeloid leukemia (AML) is a neoplastic hematologic disorder that arises at the level of a primitive stem/progenitor cell.
  • Most studies on the biology of the hematopoietic system in AML have focused on cells from adult patients; much less is known about hematopoietic cells from childhood AML.
  • A major difference, however, as compared to hematopoietic progenitors from normal subjects, was the fact that whereas in cultures of normal cells both myeloid and erythroid precursors were produced, in AML cultures the vast majority of the cells generated corresponded to myeloid cells, mostly mature macrophages.
  • [MeSH-major] Bone Marrow Cells / pathology. Hematopoietic Stem Cells / pathology. Leukemia, Myeloid, Acute / blood

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18680148.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Cytokines
  •  go-up   go-down


22. Batova A, Cottam H, Yu J, Diccianni MB, Carrera CJ, Yu AL: EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. Blood; 2006 Feb 1;107(3):898-903
Hazardous Substances Data Bank. (L)-ALANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.
  • The deficiency of methylthioadenosine phosphorylase (MTAP) in T-cell acute lymphoblastic leukemia (T-ALL) and other cancers, while constitutively expressed in normal cells, allows for selective therapy using L-alanosine, an inhibitor of de novo AMP synthesis.
  • The cytotoxicity of EFA to hematopoietic progenitors erythroid burst-forming units (BFU-Es) and granulocyte-macrophage colony-forming units (CFU-GMs) was at least 26- to 41-fold less than that of MTA.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurochem. 1989 Sep;53(3):800-6 [2547901.001]
  • [Cites] Blood. 1989 Mar;73(4):952-60 [2920215.001]
  • [Cites] Mol Cell Biol. 1992 Jan;12(1):103-11 [1729592.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1098-101 [8382555.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2410-5 [7683574.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3396-7 [8012957.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6353-8 [7987828.001]
  • [Cites] J Med Chem. 1995 Mar 31;38(7):1174-88 [7707320.001]
  • [Cites] Blood. 1995 May 1;85(9):2321-30 [7727766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6489-93 [7604019.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6203-8 [8650244.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3083-90 [8874207.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5653-8 [8971171.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2602-5 [9205063.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):433-8 [9815702.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1492-7 [10197619.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2108-13 [12796375.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):683-90 [12875987.001]
  • [Cites] Biochem Pharmacol. 2003 Aug 15;66(4):613-21 [12906926.001]
  • [Cites] Oncol Res. 2004;14(7-8):373-9 [15301428.001]
  • [Cites] J Pharm Sci. 1967 Jul;56(7):865-70 [4962273.001]
  • [Cites] Biochem Pharmacol. 1968 Mar;17(3):363-8 [5690813.001]
  • [Cites] Biochem J. 1969 Nov;115(2):241-7 [5378381.001]
  • [Cites] Biochem Biophys Res Commun. 1978 Jul 14;83(1):27-35 [100109.001]
  • [Cites] Biochem Pharmacol. 1978;27(17):2163-9 [310308.001]
  • [Cites] Circ Res. 1979 Oct;45(4):468-78 [476869.001]
  • [Cites] Biochem Pharmacol. 1980 Feb;29(2):227-45 [7362636.001]
  • [Cites] Can J Physiol Pharmacol. 1980 Jun;58(6):673-91 [6253037.001]
  • [Cites] Cancer Res. 1980 Dec;40(12):4390-7 [7438071.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1533-5 [7007366.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Feb;78(2):1219-23 [6785752.001]
  • [Cites] Blood. 1982 Dec;60(6):1387-91 [6814551.001]
  • [Cites] Clin Chim Acta. 1983 Mar 14;128(2-3):283-90 [6406103.001]
  • [Cites] Adv Pharmacol Chemother. 1984;20:69-121 [6398969.001]
  • [Cites] Mutat Res. 1986 Jun;161(1):1-7 [3517630.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5409-12 [3093064.001]
  • [Cites] Breast Cancer Res Treat. 1987;9(1):53-9 [3109530.001]
  • [Cites] Blood. 1988 Jun;71(6):1568-73 [3130904.001]
  • [Cites] Biochem Pharmacol. 1988 May 15;37(10):2085-9 [3377811.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3193-7 [1904005.001]
  • (PMID = 16234352.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00827
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 9-beta-D-erythrofuranosyladenine; 0 / Antibiotics, Antineoplastic; 0 / Deoxyadenosines; 0 / Enzyme Inhibitors; 0 / Furans; 0 / Thionucleosides; 2CNI71214Y / alanosine; 634Z2VK3UQ / 5'-methylthioadenosine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 2.4.2.28 / 5'-methylthioadenosine phosphorylase; JAC85A2161 / Adenine; OF5P57N2ZX / Alanine
  • [Other-IDs] NLM/ PMC1895892
  •  go-up   go-down


23. Khalil F, Cualing H, Cogburn J, Miles L: The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study. Arch Pathol Lab Med; 2007 Aug;131(8):1281-9
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study.
  • OBJECTIVE: To study the rate of recovery of bone marrow in patients given myelosuppressive therapy for acute myelogenous leukemia, establish the histologic criteria of recovered marrow, and correlate the recovery pattern with those patients who received a bone marrow transplant by using histology, peripheral blood, immunophenotyping, and computerized morphometry and mathematical slope equation.
  • These patients were divided into 2 groups: 1 group of 28 cases diagnosed with acute myeloid leukemia, the majority treated with cytarabine (Ara-C) infusion for 7 days and daunorubicin intravenously daily for 3 days (7+3 regimen), and the other control group of 23 cases treated with chemotherapy or allogeneic bone marrow transplantation for a variety of hematologic malignancies.
  • We used morphometry to calculate the cellularity and myeloid to erythroid ratio and quantified megakaryocytes CD10 versus time from day 14 onward.
  • After regenerative hyperplasia, the cellularity plateaus, the myeloid to erythroid ratio, and the megakaryocytes even out with platelet normalization, and the early CD10+ B cells rise from day 40 onward, P = .01.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / physiology. Bone Marrow Transplantation. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / physiopathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Biopsy. Blood Cell Count. Combined Modality Therapy. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Image Processing, Computer-Assisted. Immunophenotyping. Male. Middle Aged. Recovery of Function. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17683190.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


24. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol; 2008 Nov 1;26(31):5078-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
  • PURPOSE: To evaluate the prognostic significance of CEBPA mutations in the context of established molecular markers in cytogenetically normal (CN) acute myeloid leukemia (AML) and gain biologic insights into leukemogenesis of the CN-AML molecular high-risk subset (FLT3 internal tandem duplication [ITD] positive and/or NPM1 wild type) that has a significantly higher incidence of CEBPA mutations than the molecular low-risk subset (FLT3-ITD negative and NPM1 mutated).
  • The major features of these profiles were upregulation of genes (eg, GATA1, ZFPM1, EPOR, and GFI1B) and miRNAs (ie, the miR-181 family) involved in erythroid differentiation and downregulation of homeobox genes.
  • The gene and miRNA expression profiling provided insights into leukemogenesis of the CN-AML molecular high-risk group, indicating that CEBPA mutations are associated with partial erythroid differentiation.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Feb 15;99(4):1332-40 [11830484.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3770-81 [12110589.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2717-23 [12351377.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4372-80 [12393388.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2206-14 [12406909.001]
  • [Cites] Hematol J. 2003;4(1):31-40 [12692518.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] Immunity. 2003 Sep;19(3):451-62 [14499119.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):394-400 [15122210.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4290-301 [15514371.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1418-25 [8640834.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8705-10 [10411939.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1372-9 [15746035.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1416-24 [15746041.001]
  • [Cites] Blood. 2005 Jul 15;106(2):673-80 [15797998.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3618-20 [16046528.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3740-6 [16051734.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3733-9 [16076867.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9234-42 [16275934.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):790-7 [16418499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6338-43 [16606850.001]
  • [Cites] Blood. 2006 May 15;107(10):4011-20 [16455956.001]
  • [Cites] Curr Opin Hematol. 2006 Jul;13(4):203-8 [16755214.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Blood. 2007 Jan 1;109(1):389-90 [17190859.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):551-64 [17379065.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5164-7 [17341662.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2493-4; author reply 2494-5 [17557966.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3337-43 [17577018.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6766-76 [17934484.001]
  • [Cites] Nucleic Acids Symp Ser (Oxf). 2007;(51):415-6 [18029763.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):51-60 [17994017.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1552-9 [17940205.001]
  • [Cites] Leukemia. 2008 Mar;22(3):655-7 [17851556.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1919-28 [18450603.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5371-9 [18378853.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):263-70 [11242107.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [CommentIn] J Clin Oncol. 2009 Apr 20;27(12):2105; author reply 2106 [19273693.001]
  • [ErratumIn] J Clin Oncol. 2008 Dec 20;26(36):6021
  • (PMID = 18809607.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA09512; United States / NCI NIH HHS / CA / CA089341; United States / NCI NIH HHS / CA / CA96887; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA98933; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA90469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAALC protein, human; 0 / Biomarkers, Tumor; 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / ERG protein, human; 0 / MLL protein, human; 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Trans-Activators; 0 / WT1 Proteins; 117896-08-9 / nucleophosmin; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2652095
  •  go-up   go-down


25. Brunet de la Grange P, Armstrong F, Duval V, Rouyez MC, Goardon N, Romeo PH, Pflumio F: Low SCL/TAL1 expression reveals its major role in adult hematopoietic myeloid progenitors and stem cells. Blood; 2006 Nov 1;108(9):2998-3004
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low SCL/TAL1 expression reveals its major role in adult hematopoietic myeloid progenitors and stem cells.
  • Stem cell leukemia/T cell acute leukemia 1 (SCL/TAL1) plays a key role in the development of murine primitive hematopoiesis but its functions in adult definitive hematopoiesis are still unclear.
  • Using lentiviral delivery of TAL1-directed shRNA in human hematopoietic cells, we show that decreased expression of TAL1 induced major disorders at different levels of adult hematopoietic cell development.
  • Erythroid and myeloid cell production in cultures was dramatically decreased in TAL1-directed shRNA-expressing cells, whereas lymphoid B-cell development was normal.
  • These results confirm the role of TAL1 in the erythroid compartment and show TLA1's implication in the function of myeloid committed progenitors.
  • Altogether, these observations definitively show that TAL1 participates in the regulation of hematopoiesis from HSCs to myeloid progenitors, and pinpoint TAL1 as a master protein of human and murine adult hematopoiesis.
  • [MeSH-minor] Adult. Animals. Cell Culture Techniques. Colony-Forming Units Assay. Gene Expression Regulation. Humans. Infant. Intracellular Signaling Peptides and Proteins. Mice. Mice, Inbred NOD. Stem Cells / physiology. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849639.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins, Fusion; 0 / SIL protein, mouse; 0 / STIL protein, human
  •  go-up   go-down


26. Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, Wojnar J, Markiewicz M, Wojciechowska-Sadus M, Kopera M, Kruzel T, Najda J, Nowak K, Holowiecki J: Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Haematologica; 2005 Nov;90 Suppl:ECR33
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
  • We describe two patients with acute myeloid leukemia successfully treated with anti-CD20 antibody for pure red cell aplasia (PRCA) following ABO-mismatched allogeneic hematopoietic stem cell transplantation (HSCT).
  • PRCA following HSCT is associated with major ABO incompatibility between donor and recipient and is due to an inhibition of donor erythroid precursors by residual host isoagglutinins.
  • [MeSH-major] ABO Blood-Group System / immunology. Antibodies, Monoclonal / therapeutic use. Blood Group Incompatibility / complications. Hematopoietic Stem Cell Transplantation / adverse effects. Immunosuppressive Agents / therapeutic use. Immunotherapy. Leukemia, Monocytic, Acute / surgery. Leukemia, Myeloid, Acute / surgery. Peripheral Blood Stem Cell Transplantation / adverse effects. Postoperative Complications / drug therapy. Red-Cell Aplasia, Pure / drug therapy. Transplantation, Homologous / adverse effects
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Aspergillosis / etiology. Female. Humans. Immunocompromised Host. Lung Diseases, Fungal / etiology. Male. Middle Aged. Rituximab. Shock, Septic / etiology

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266924.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


27. Us T, Ozune L, Kasifoglu N, Akgun Y: The investigation of parvovirus B19 infection in patients with haematological disorders by using PCR and ELISA techniques. Braz J Infect Dis; 2007 Jun;11(3):327-30
MedlinePlus Health Information. consumer health - Blood Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parvovirus B19 has a marked tropism for erythroid progenitor cells.
  • B19 infection was established in 3 of 11 patients with chronic myeloid leukemia, in 3 of 11 acute myeloid leukemia, in 2 of 11 patients with multiple myeloma, in 3 of 8 patients with Hodgkin's lymphoma, in 5 of 10 patients with non-Hodgkin's lymphoma, in 1 of 6 patients with myelodysplastic syndrome, in 4 of 11 patients with chronic lymphocytic leukemia, and in 2 of 11 patients with acute lymphocytic leukemia.
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Antibodies, Viral / blood. Chronic Disease. DNA, Viral / analysis. Enzyme-Linked Immunosorbent Assay. Female. Hodgkin Disease / virology. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Leukemia / virology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Polymerase Chain Reaction. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684634.001).
  • [ISSN] 1413-8670
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


28. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH: Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet; 2005 Jun;37(6):613-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired mutations in the hematopoietic transcription factor GATA binding protein-1 (GATA1) are found in megakaryoblasts from nearly all individuals with Down syndrome with transient myeloproliferative disorder (TMD, also called transient leukemia) and the related acute megakaryoblastic leukemia (DS-AMKL, also called DS-AML M7).
  • Our observations raise the possibility that the target cells in other leukemias of infancy and early childhood are distinct from those in adult leukemias and underscore the interplay between specific oncoproteins and potential target cells.
  • [MeSH-minor] Adult. Age Factors. Animals. Cell Differentiation. Cells, Cultured. Down Syndrome / genetics. Embryo, Mammalian. Erythroid-Specific DNA-Binding Factors. GATA1 Transcription Factor. Gene Targeting. Hematopoiesis / genetics. Humans. Infant. Leukemia, Megakaryoblastic, Acute / genetics. Liver / cytology. Liver / embryology. Megakaryocytes. Mice. Transfection


29. Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R: Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol; 2005 Dec;75(6):485-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Enhanced bone marrow (BM) angiogenesis is regarded as an essential cofactor in the progression of MDS to acute myelogenous leukemia (AML) and microvessel formation may be induced by TNF-alpha as well.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Erythroid Precursor Cells / metabolism. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / metabolism. Myelodysplastic Syndromes / metabolism. Tumor Necrosis Factor-alpha / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biopsy / methods. Bone Marrow / blood supply. Bone Marrow / metabolism. Bone Marrow / pathology. Case-Control Studies. Disease-Free Survival. Erythropoiesis. Female. Humans. Male. Microcirculation / metabolism. Microcirculation / pathology. Middle Aged. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Predictive Value of Tests


30. Lessard M, Struski S, Leymarie V, Flandrin G, Lafage-Pochitaloff M, Mozziconacci MJ, Talmant P, Bastard C, Charrin C, Baranger L, Hélias C, Cornillet-Lefebvre P, Mugneret F, Cabrol C, Pagès MP, Fert-Ferret D, Nguyen-Khac F, Quilichini B, Barin C, Berger R, Groupe Francophone de Cytogénétique Hématologique (GFCH): Cytogenetic study of 75 erythroleukemias. Cancer Genet Cytogenet; 2005 Dec;163(2):113-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective study of 75 EL defined following the WHO classification was performed by the Groupe Francophone de Cytogénétique Hématologique (GFCH) in order to reexamine the cytogenetics of this infrequent leukemia subtype.
  • Four out of 7 cases of "pure erythroid" leukemia were associated with a BCR-ABL fusion.
  • However, the large overlap of chromosomal abnormality patterns of EL (pure erythroid form excepted) and refractory anemia with excess of blasts in transformation (RAEB-t) favors the hypothesis of similarities between these 2 hematologic disorders.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Erythroblastic, Acute / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Chromosomes, Human. Humans. Middle Aged. Ploidies. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337853.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Jha A, Sayami G, Adhikari RC, Panta AD, Jha R: Bone marrow examination in cases of pancytopenia. JNMA J Nepal Med Assoc; 2008 Jan-Mar;47(169):12-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Erythroid hyperplasia was seen in 29 cases (19.6%) and normal bone marrow was seen in 5 cases (3.38%).
  • Acute leukemia was the commonest hematological malignancy.
  • [MeSH-minor] Adolescent. Adult. Aged. Anemia, Aplastic. Anemia, Megaloblastic / pathology. Bone Marrow Examination. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Infant. Leukemia. Male. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552886.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


32. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, Zauli G: Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol; 2005 Feb;166(2):557-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We focused our study on the cytokine TRAIL (TNF-related apoptosis-inducing ligand), which has been shown to exhibit an anti-differentiation activity on erythroid maturation.
  • Immunocytochemical analysis of bone marrow mononuclear cells (BMMC) showed an increased expression of TRAIL in MDS patients with respect to acute myeloid leukemia (AML) patients and normal BM donors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / biosynthesis. Apoptosis. Apoptosis Regulatory Proteins. Bone Marrow Cells / metabolism. Culture Media, Conditioned / pharmacology. Culture Media, Serum-Free / metabolism. Enzyme-Linked Immunosorbent Assay. Erythrocytes / metabolism. Female. Fetal Blood / metabolism. Flow Cytometry. Glycophorin / metabolism. Humans. Immunohistochemistry. Leukemia, Myeloid, Acute / blood. Leukocytes, Mononuclear / metabolism. Ligands. Male. Middle Aged. TNF-Related Apoptosis-Inducing Ligand. Time Factors

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Apr;37(3-4):405-14 [10752992.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4210-8 [15315976.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1388-92 [10942382.001]
  • [Cites] Exp Hematol. 2000 Aug;28(8):941-9 [10989195.001]
  • [Cites] Int J Hematol. 2000 Aug;72(2):131-3 [11039659.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3932-8 [11090080.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3058-65 [11698291.001]
  • [Cites] Exp Hematol. 2001 Dec;29(12):1484-93 [11750108.001]
  • [Cites] Leukemia. 2002 Jan;16(1):67-73 [11840265.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1594-601 [11861273.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):119-26 [11918541.001]
  • [Cites] Leukemia. 2002 May;16(5):785-90 [11986938.001]
  • [Cites] Int J Hematol. 2002 Apr;75(3):289-97 [11999358.001]
  • [Cites] Leuk Res. 2002 Jul;26(7):687-8 [12008087.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):66-75 [12655296.001]
  • [Cites] Cytokine. 2003 Dec 21;24(6):244-53 [14609566.001]
  • [Cites] Blood. 2004 Jan 15;103(2):517-22 [12969966.001]
  • [Cites] J Exp Med. 2004 Mar 15;199(6):785-95 [15007095.001]
  • [Cites] Blood. 1995 Jul 1;86(1):268-76 [7795232.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3064 [8639933.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12687-90 [8663110.001]
  • [Cites] Leukemia. 1997 Jun;11(6):839-45 [9177438.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):176-88 [9792306.001]
  • [Cites] Nat Med. 1999 Feb;5(2):157-63 [9930862.001]
  • [Cites] Int J Hematol. 1999 Apr;69(3):152-9 [10222652.001]
  • [Cites] N Engl J Med. 1999 May 27;340(21):1649-60 [10341278.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Nature. 1999 Sep 30;401(6752):489-93 [10519553.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3716-24 [10845902.001]
  • (PMID = 15681838.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Apoptosis Regulatory Proteins; 0 / Culture Media, Conditioned; 0 / Culture Media, Serum-Free; 0 / Glycophorin; 0 / Ligands; 0 / Membrane Glycoproteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC1602326
  •  go-up   go-down


33. Linardi Cda C, Pracchia LF, Buccheri V: Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution. Sao Paulo Med J; 2008 Jan 2;126(1):52-7
Genetic Alliance. consumer health - Polycythemia vera.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT AND OBJECTIVE: Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by predominant proliferation of erythroid precursors.
  • Clinical and demographic characteristics, thrombotic events, transformation to acute leukemia, myelofibrosis and survival were evaluated.
  • The overall incidence of leukemia and myelofibrosis was 0.42% per patient-year and 1.06% per patient-year, respectively.
  • [MeSH-minor] Adult. Brazil / epidemiology. Epidemiologic Methods. Female. Hemoglobins / analysis. Humans. Leukemia / etiology. Male. Middle Aged. Platelet Count. Thrombosis / complications. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425288.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


34. Peniket A, Wainscoat J, Side L, Daly S, Kusec R, Buck G, Wheatley K, Walker H, Chatters S, Harrison C, Boultwood J, Goldstone A, Burnett A: Del (9q) AML: clinical and cytological characteristics and prognostic implications. Br J Haematol; 2005 Apr;129(2):210-20
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Del (9q) is a recurrent cytogenetic abnormality in acute myeloid leukaemia (AML).
  • There was also an association with erythroid dysplasia (74%) and granylocytic lineage vacuolation (90%).
  • [MeSH-major] Gene Deletion. Genes, Tumor Suppressor. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Bone Marrow Cells / pathology. Child. Child, Preschool. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Cytogenetic Analysis. Disease-Free Survival. Female. Genetic Markers. Humans. Male. Middle Aged. Survival Rate. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2005 Sep;130(6):969; author reply 969 [16156871.001]
  • (PMID = 15813849.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


35. Le Clech M, Chalhoub E, Dohet C, Roure V, Fichelson S, Moreau-Gachelin F, Mathieu D: PU.1/Spi-1 binds to the human TAL-1 silencer to mediate its activity. J Mol Biol; 2006 Jan 6;355(1):9-19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The TAL-1/SCL gene encodes a basic helix-loop-helix (bHLH) transcription factor essential for primitive hematopoiesis and for adult erythroid and megakaryocytic development.
  • Activated transcription of TAL-1 as a consequence of chromosomal rearrangements is associated with a high proportion of human T cell acute leukemias, showing that appropriate control of TAL-1 is crucial for the formation and subsequent fate of hematopoietic cells.
  • Here, we show that tal-RE-binding activity, high in immature human hematopoietic progenitors is down regulated upon erythroid and megakaryocytic differentiation.
  • [MeSH-minor] Cell Line, Tumor. Down-Regulation. Hematopoiesis / genetics. Humans. Leukemia / pathology. Protein Binding. Response Elements. Transcription Factors. Transcriptional Activation. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298389.001).
  • [ISSN] 0022-2836
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 0 / proto-oncogene protein Spi-1; EC 6.3.2.19 / LRSAM1 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


36. Yang Y, Létard S, Borge L, Chaix A, Hanssens K, Lopez S, Vita M, Finetti P, Birnbaum D, Bertucci F, Gomez S, de Sepulveda P, Dubreuil P: Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood; 2010 Aug 19;116(7):1114-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although most adult patients have a D(816)V mutation in phosphotransferase domain (PTD), we have described that half of the children carry mutations in extracellular domain (ECD).
  • PTD mutants failed to support colony formation and erythropoietin-mediated erythroid differentiation.
  • Consistently, AKT inhibitor suppressed ECD mutant-dependent proliferation, clonogenicity, and erythroid differentiation.
  • Expression of myristoylated AKT restored erythroid differentiation in EML-PTD cells, suggesting the differential role of AKT in those mutants.
  • Overall, our study implied different pathogenesis of pediatric versus adult mastocytosis, which might explain their diverse phenotypes.
  • [MeSH-minor] Adult. Animals. Apoptosis. Blotting, Western. Cells, Cultured. Child. Fibroblasts / cytology. Fibroblasts / metabolism. Flow Cytometry. Humans. Leukemia, Erythroblastic, Acute / metabolism. Leukemia, Erythroblastic, Acute / pathology. Lymphocytes / metabolism. Mast Cells / metabolism. Mice. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / genetics. Rats. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Mast cell disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20484085.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


37. Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E: Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood; 2005 Aug 1;106(3):803-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Erythroid response rate was 39% and median response duration 23 months (range, 3-116 months or more).
  • The time until 25% developed acute myeloid leukemia (AML) was longer in the good and intermediate predictive groups for erythroid response compared with the poor predictive group (52 versus 13 months, P = .008).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Cell Transformation, Neoplastic. Female. Humans. Leukemia, Myeloid / etiology. Male. Middle Aged. Predictive Value of Tests. Prognosis. Survival Analysis. Treatment Outcome


38. Ishikawa T, Tohyama K, Nakao S, Yoshida Y, Teramura M, Motoji T, Takatoku M, Kurokawa M, Mitani K, Uchiyama T, Omine M: A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response. Int J Hematol; 2007 Aug;86(2):150-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 19 patients evaluated, 10 showed hematologic improvement; 8 patients showed an erythroid response, 6 showed a platelet response, and one showed a neutrophil response.
  • Most toxicities associated with CSA usage were manageable, and no patient had developed acute leukemia up to this point.
  • A minority of RA patients who did not possess such predictive variables achieved an isolated erythroid response.
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD55 / analysis. Antigens, CD59 / analysis. Erythrocyte Count. Female. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Neutrophils / cytology. Platelet Count. Prognosis. Prospective Studies. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875530.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD55; 0 / Antigens, CD59; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


39. Reynaud D, Ravet E, Titeux M, Mazurier F, Rénia L, Dubart-Kupperschmitt A, Roméo PH, Pflumio F: SCL/TAL1 expression level regulates human hematopoietic stem cell self-renewal and engraftment. Blood; 2005 Oct 1;106(7):2318-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem cell leukemia/T-cell acute lymphoblastic leukemia 1 (SCL/TAL1), a basic helix-loop-helix (bHLH) transcription factor, plays key roles in controlling the development of primitive and definitive hematopoiesis during mouse development but its function in adult HSCs is still a matter of debate.
  • As a consequence, the production of SRC-derived multipotent progenitors as well as erythroid- and myeloid-differentiated cells is increased.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15961517.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Antigens, CD15; 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins, Fusion; 0 / STIL protein, human; 147336-22-9 / Green Fluorescent Proteins; 9007-49-2 / DNA
  •  go-up   go-down


40. Migliaccio G, Di Baldassarre A, Di Rico C, Di Noia A, Nakamoto B, Cao H, Skarpidi E, Migliaccio AR: Spontaneous switch from Agamma- to beta-globin promoter activity in a stable transfected dual reporter vector. Blood Cells Mol Dis; 2005 Mar-Apr;34(2):174-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the activity driven by the beta-promoter increased 10-fold more than that driven by the (A)gamma one, the ratio between (A)gamma-driven/((A)gamma-driven + beta-driven) reporter activity in the cells decreased after 1 month and became similar to the gamma/(gamma + beta) globin mRNA ratio expressed by adult erythroid cells.
  • These results suggest that the rapid changes in activity driven by the (A)gamma- and beta-globin promoters occurring during the first month after transfection may represent a novel in vitro model to study epigenetic regulation of the (A)gamma- and beta-promoter during the fetal to adult hemoglobin switch and confirm GM979 cells stably transfected with the dual reporter construct as a reliable assay for automated screening of chemical inducers of fetal globin gene activation.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cloning, Molecular. Fetal Hemoglobin / genetics. Genes, Reporter. Genetic Vectors. Humans. Leukemia, Erythroblastic, Acute. Luciferases / genetics. Mice. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15727902.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Grant] Italy / Telethon / / E.1172; United States / NHLBI NIH HHS / HL / HL20899
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9004-22-2 / Globins; 9034-63-3 / Fetal Hemoglobin; EC 1.13.12.- / Luciferases
  •  go-up   go-down


41. Müller-Berndorff H, Haas PS, Kunzmann R, Schulte-Mönting J, Lübbert M: Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis. Ann Hematol; 2006 Aug;85(8):502-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We retrospectively studied 89 consecutive patients diagnosed with primary myelodysplastic syndrome (MDS) over a period of 10 years to (1) identify prognostic factors for overall survival (OS) and leukemia-free survival (LFS);.
  • Median OS was 3 years; 67 patients (75%) have died, and 28 (31%) had progression to acute myeloid leukemia (AML).
  • The new WHO subgroups [refractory cytopenia with multilineage dysplasia (RCMD), with (RCMD-RS) or without ringed sideroblasts] showed a significantly (P = 0.0454) different prognosis for OS, but not for LFS (P = 0.0839), in comparison to the subgroups having erythroid dysplasia only (RA/RARS).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. World Health Organization

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715299.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


42. Kuroyanagi Y, Kaneko Y, Muta K, Park BS, Moi P, Ausenda S, Cappellini MD, Ikuta T: cAMP differentially regulates gamma-globin gene expression in erythroleukemic cells and primary erythroblasts through c-Myb expression. Biochem Biophys Res Commun; 2006 Jun 9;344(3):1038-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently found that, upon activation of the cAMP pathway, expression of the gamma-globin gene is inhibited in K562 cells but induced in adult erythroblasts.
  • Importantly, forskolin-induced erythroid differentiation in K562 cells, as determined by the expression of glycophorins and CD71, suggesting that high-level expression of c-Myb may not be sufficient to inhibit the differentiation of erythroid cells.
  • In contrast, c-Myb was not expressed in adult erythroblasts treated with forskolin and primary erythroblasts may lack the c-Myb-mediated inhibitory mechanism for gamma-globin gene expression.
  • Together, these results show that the cAMP pathway blocks gamma-globin gene expression in K562 cells by increasing c-Myb expression and c-Myb plays a role in defining the mode of response of the gamma-globin gene to fetal hemoglobin inducers in erythroid cells.
  • [MeSH-major] Cyclic AMP / metabolism. Erythroblasts / metabolism. Gene Expression Regulation / physiology. Globins / metabolism. Leukemia, Erythroblastic, Acute / metabolism. Proto-Oncogene Proteins c-myb / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631597.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK61806; United States / NHLBI NIH HHS / HL / R01HL73452
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myb; 9004-22-2 / Globins; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


43. Breccia M, Carmosino I, Biondo F, Mancini M, Russo E, Latagliata R, Alimena G: Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes. Leuk Res; 2006 Feb;30(2):178-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to this system, FAB low risk MDS (RA and RARS) were defined as such when the presence of dysplastic features was only restricted to the erythroid lineage, and new categories, refractory cytopenia with multilineage dysplasia (RCMD) and refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS), were added.
  • Furthermore we confirmed the usefulness of WHO segregation with regard to its predictive value for evolution into acute leukaemia.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. World Health Organization

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102825.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Benites BD, Traina F, Duarte Ada S, Lorand-Metze IG, Costa FF, Saad ST: Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia. Eur J Haematol; 2010 Jun;84(6):525-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to characterize the mRNA expression levels of APAF-1 transcripts in low-risk and high-risk MDS and to elucidate whether the expression levels of APAF-1 transcripts are modulated with increased apoptosis in CD34(+) MDS cells undergoing erythroid differentiation.
  • METHODS: APAF-1 (NM_181861) expression was verified, by quantitative RT-PCR, in bone marrow aspirates from 33 patients with myelodysplastic syndromes (MDS), at the time of diagnosis, and in erythroid differentiation cultures from CD34(+) from normal donors and patients with MDS.
  • Low-risk MDS-derived differentiated erythroid cells demonstrated an increased expression of APAF-1, compared with normal cells, accompanied by an augmented rate of apoptosis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia, Refractory / genetics. Anemia, Refractory, with Excess of Blasts / genetics. Anemia, Sideroblastic / genetics. Apoptosis / genetics. Base Sequence. Cell Differentiation / genetics. DNA Primers / genetics. Erythropoiesis / genetics. Female. Gene Expression. Humans. Leukemia, Myeloid, Acute / genetics. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Risk Factors

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20345447.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / DNA Primers; 0 / RNA, Messenger
  •  go-up   go-down


45. Moore A, Merad Boudia M, Lehalle D, Massrieh W, Derjuga A, Blank V: Regulation of globin gene transcription by heme in erythroleukemia cells: analysis of putative heme regulatory motifs in the p45 NF-E2 transcription factor. Antioxid Redox Signal; 2006 Jan-Feb;8(1-2):68-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast to MEL cells, CB3 cells are null for p45 and thus express only extremely low levels of adult globin transcripts upon induction by agents promoting erythroid differentiation.
  • [MeSH-minor] Animals. Blotting, Northern. Cell Line, Tumor. DNA Primers. Hemin / biosynthesis. Leukemia, Erythroblastic, Acute. Mice. Mutagenesis, Site-Directed. Protein Subunits / metabolism. Transcriptional Activation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487039.001).
  • [ISSN] 1523-0864
  • [Journal-full-title] Antioxidants & redox signaling
  • [ISO-abbreviation] Antioxid. Redox Signal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / NF-E2 Transcription Factor, p45 Subunit; 0 / Protein Subunits; 42VZT0U6YR / Heme; 743LRP9S7N / Hemin; 9004-22-2 / Globins
  •  go-up   go-down


46. Gulen H, Basarir F, Hakan N, Ciftdogan DY, Tansug N, Onag A: Premature labor and leukoerythroblastosis in a newborn with parvovirus B19 infection. Haematologica; 2005 Nov;90 Suppl:ECR38
MedlinePlus Health Information. consumer health - Premature Babies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leukoerythroblastosis is a rarely observed disease characterized by the presence of leukocytosis, erythroid and myeloid blast cells in peripheral blood.
  • The etiological factors observed in leukoerythroblastosis occurring during neonatal and early childhood period are congenital-postnatal viral infections, juvenile myelomonocytic leukemia and osteopetrosis.
  • Leukoerythroblastosis is a rarely observed disease characterized by the presence of leukocytosis, erythroid and myeloid blast cells in peripheral blood.
  • It is reported that it can be observed following hematologic malignancies especially juvenile myelomonocytic leukemia, acute infections, hemolytic anemia, osteopetrosis, myelofibrosis, neuroblastoma and taking certain medicines.
  • [MeSH-minor] Adult. Antibodies, Viral / blood. Blood Transfusion. Female. Fetal Diseases / virology. Gestational Age. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Infant, Newborn. Infant, Premature. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266929.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


47. Blin N, Traineau R, Houssin S, Peffault de Latour R, Petropoulou A, Robin M, Larghero J, Ribaud P, Socié G: Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant; 2010 Sep;16(9):1315-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median time to red cell transfusion independence was significantly longer in ABO-incompatible BM recipients (median time, 63 days vs 41 days; P =.001), with faster disappearance of antidonor IgM hemagglutinins in unrelated recipients (median time, 36 days vs 44 days; P = .03) and in patients with grade > or =II acute GVHD (aGVHD) (median time, 35 days vs 59 days ; P = .001).
  • In PB stem cell (PBSC) and CB transplantation, erythroid reconstitution was not significantly delayed, regardless of donor type or presence of aGVHD.
  • In patients with acute leukemia, multivariate analysis revealed an association between major ABO mismatch and decreased relapse rate with borderline statistical significance (hazard ratio, 0.65; P = .04).
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20353831.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System
  •  go-up   go-down


48. Garban F, Drillat P, Makowski C, Jacob MC, Richard MJ, Favrot M, Sotto JJ, Bensa JC, Cahn JY: Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica; 2005 Aug;90(8):1096-101
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: Extracorporeal chemophototherapy (ECP) is considered an immunomodulatory agent useful in both acute and chronic graft-versus-host disease (GVHD).
  • RESULTS: Nine out of 12 patients with acute GVHD responded to treatment.
  • INTERPRETATION AND CONCLUSIONS: ECP is effective in both chronic and acute GVHD, particularly in lung forms.
  • ECP can reduce the duration of immunosuppressive therapy and improve erythroid recovery.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Hematologic Neoplasms / therapy. Leukemia / therapy. Lymphoma, Non-Hodgkin / therapy. Photochemotherapy / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Busulfan / therapeutic use. Female. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Survival Analysis. Transplantation Conditioning / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Aug;90(8):1013B [16079096.001]
  • (PMID = 16079109.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; G1LN9045DK / Busulfan
  •  go-up   go-down


49. Murati A, Gelsi-Boyer V, Adélaïde J, Perot C, Talmant P, Giraudier S, Lodé L, Letessier A, Delaval B, Brunel V, Imbert M, Garand R, Xerri L, Birnbaum D, Mozziconacci MJ, Chaffanet M: PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia; 2005 Sep;19(9):1692-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.
  • [MeSH-major] Cell Cycle Proteins / genetics. Leukemia, Erythroblastic, Acute / genetics. Myeloproliferative Disorders / genetics. Oncogene Proteins, Fusion / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Autoantigens. Child. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Female. Humans. Janus Kinase 2. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034466.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Cell Cycle Proteins; 0 / Oncogene Proteins, Fusion; 0 / PCM1 protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down






Advertisement